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SUMMARY

Despite therapeutic interventions for glioblastoma (GBM), cancer stem cells (CSCs) drive recurrence. The
precise mechanisms underlying CSC resistance, namely inhibition of cell death, are unclear. We built on previous observations that the high cell surface expression of junctional adhesion molecule-A drives CSC maintenance and identified downstream signaling networks, including the cysteine protease inhibitor SerpinB3.
Using genetic depletion approaches, we found that SerpinB3 is necessary for CSC maintenance, survival,
and tumor growth, as well as CSC pathway activation. Knockdown of SerpinB3 also increased apoptosis
and susceptibility to radiation therapy. SerpinB3 was essential to buffer cathepsin L-mediated cell death,
which was enhanced with radiation. Finally, we found that SerpinB3 knockdown increased the efficacy of radiation in pre-clinical models. Taken together, our findings identify a GBM CSC-specific survival mechanism
involving a cysteine protease inhibitor, SerpinB3, and provide a potential target to improve the efficacy of
GBM therapies against therapeutically resistant CSCs.

INTRODUCTION
Glioblastoma (GBM; World Health Organization [WHO] grade 4
glioma) is the most common primary malignant brain tumor
and remains uniformly lethal. Despite aggressive therapies,
including maximal safe surgical resection, radiation, and chemotherapy, GBM patients experience a median survival of approximately 20 months (Stupp et al., 2005, 2017). GBM therapeutic
resistance has been associated with poor brain penetration of
compounds due to the blood-brain barrier (Bellettato and
Scarpa, 2018; Harder et al., 2018), cellular heterogeneity and
plasticity (Lauko et al., 2021), and limited immune infiltration
(Martinez-Lage et al., 2019; Pombo Antunes et al., 2020). The
cellular heterogeneity is driven by populations of cancer stem
cells (CSCs) (Gimple et al., 2019; Lathia et al., 2015), and recent

studies have demonstrated that GBM contains a high degree of
plasticity, with the CSC state being linked to cellular programs,
including wound healing, development, and metabolic fluidity
(Garnier et al., 2019; Mitchell et al., 2021; Pelaz et al., 2020)
that underlie tumor growth and therapeutic resistance.
CSCs are functionally defined by their ability to self-renew
and initiate a tumor upon secondary transplantation. Moreover,
CSCs possess enhanced molecular mechanisms of therapeutic
resistance, including DNA repair (Bao et al., 2006) and drug efflux
pumps (Mason, 2015). In addition, CSCs can be subject
to stressful environments, including hypoxia and necrosis, and,
although some mechanisms have been proposed as to how
these cells can thrive under these stressful conditions (Alvarado
et al., 2017; Hsieh et al., 2011), the precise mechanisms
as to how CSCs evade cell death are unclear. Cell adhesion
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Figure 1. SerpinB3 is necessary for glioblastoma
(A) Graphical abstract of His-JAM-A pulldown and liquid chromatography-mass spectrometry (LC-MS) procedure.
(B) Verification of LC-MS results by western blot. His-tagged JAM-A was overexpressed in T4121 cancer stem cells (CSCs), and protein was isolated and mixed
with nickel beads. The bound fraction was subjected to immunoblotting with antibodies to SerpinB3 and JAM-A.
(C) Immunofluorescent staining demonstrating co-expression of JAM-A and SerpinB3 in T387 PDX glioblastoma tumor model (scale bar, 10 mm).
(D) JAM-A was knocked down in T4121 CSCs with 2 separate shRNA constructs, and SerpinB3 expression was measured. Actin was used as a loading control in
this and all subsequent western blots.
(E) T387 and T4121 CSCs expressing JAM-A KD2 shRNA or NT control were treated with cycloheximide, and SerpinB3 expression was measured at 6 and 12 h
post-treatment.
(F) Western blot demonstrating knockdown of SerpinB3 with each shRNA, KD1, and KD2.

(legend continued on next page)
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represents a cellular mechanism that promotes pro-survival
signaling and is enhanced in CSCs (Lathia et al., 2010, 2014).
Specifically, GBM CSCs present elevated expression of integrins (Lathia et al., 2010), cadherins (Siebzehnrubl et al., 2013),
and junctional adhesion molecule-A (JAM-A) (Alvarado et al.,
2016; Lathia et al., 2014), which drive self-renewal and promote
resistance to conventional therapies (Bao et al., 2006; Colak and
Medema, 2014). However, the CSC-specific intracellular
signaling networks that link adhesion to resistance of cell death
remain poorly defined.
Cell death is a complex and tightly regulated series of cellular
programs that cancer cells have evolved to evade (Castelli et al.,
2021; Safa, 2016). Cell death can be triggered through a variety
of mechanisms, including DNA damage, extrinsic ligands, and
stressors (including hypoxic, metabolic, and endoplasmic reticulum stress). An understudied trigger of cell death is increased
lysosomal permeability, which leads to the release of reactive
oxygen species and cathepsins (Wang et al., 2018), a diverse
family of proteases (Yadati et al., 2020) that can initiate a variety
of cell death programs. Under physiologic conditions, cathepsin
proteolytic activity is buffered by protease inhibitors, including a
family of serine(cysteine)-protease inhibitors called serpins (Heit
et al., 2013). In normal physiology, cathepsins and serpins exist
in equilibrium to prevent aberrant cell death and damage to
healthy tissues (Heit et al., 2013; Strnad et al., 2020). In GBM,
there is limited information on lysosome-mediated cell death,
which led us to hypothesize that CSCs may use serpins to counteract this mechanism of cell death. Here, we show that the CSC
programs regulated by JAM-A engage SerpinB3 downstream to
simultaneously maintain the CSC phenotype and inhibit lysosome-mediated cell death. Suppression of SerpinB3 increases
cell death, decreases self-renewal and tumor initiation, and enhances the response of CSCs to radiation via lysosomal-mediated cell death.
RESULTS
SerpinB3 complexes with JAM-A in GBM
A series of cell surface receptors has been identified, including
CD133 (Liu et al., 2006; Singh et al., 2004), CD15 (Son et al.,
2009), CD49f (Lathia et al., 2010), CD44 (Beier et al., 2007),
L1CAM (Bao et al., 2008), and JAM-A (Lathia et al., 2014) that
regulate the expression of the CSC phenotype. With rare exceptions, the molecular cascades that connect these receptors to
the downstream pluripotency machinery has not been made
clear. In previous work, we established that GBM tumor cells expressed JAM-A when cultured under CSC-enriching conditions
and that JAM-A expression was both necessary and sufficient
for in vitro self-renewal. Previous work has suggested JAM-A
signals via multiple different adaptor proteins, leading to a variety
of downstream signals (Lauko et al., 2020). Subsequently, we re-
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vealed that Akt activation functions downstream of JAM-A and
could be inhibited by microRNA-145 (miR-145) (Alvarado et al.,
2016). While these studies have also shown that JAM-A regulates expression of the pluripotency machinery in GBM through
Akt activation, our understanding of this molecular cascade is
far from complete.
To expand our understanding of JAM-A signaling, we sought
out additional binding partners using a histidine (His)-tagged
JAM-A that we introduced into the T4121 GBM patient-derived
xenograft (PDX) model. We then pulled down the His-tagged
JAM-A and identified a series of binding partners using liquid
chromatography coupled to mass spectrometry (MS; Figure 1A;
Table S1). As expected, the protein with the greatest number
of peptides identified was JAM-A itself, and we narrowed
down candidate hits from the initial list, removing those with reported non-specific binding (via CRAPome; Mellacheruvu et al.,
2013). Post-data filtration, our next strongest hit was a cysteineprotease inhibitor, SerpinB3 (also known as squamous cell
carcinoma antigen 1 [SCCA1]), which has known roles in tumor
progression in cervical, head and neck cancers, and hepatocellular carcinoma (HCC) (Cannito et al., 2015; Pontisso, 2014).
SerpinB3 has been observed in the cytoplasm and nucleus of
cells and is expressed primarily in the esophagus, nasopharynx,
and female reproductive organs in normal human physiology
(Gomes et al., 2014; Sun et al., 2017; Uhlén et al., 2015). We validated the binding of SerpinB3 to His-tagged JAM-A (Figure 1B).
We observed SerpinB3 expression in JAM-A+ CSCs in a PDX
model (Figure 1C), as well as in human GBM patient tissue
(Figures S1A and S1B). Transcriptional profiling indicated that
SerpinB3 expression was not specifically associated with any
given molecular subtype (Figure S1C). When we interrogated
multiple PDX models grown in CSC conditions, over 95% of cells
were double positive for SerpinB3 and JAM-A (Figure S1D). In
addition, we observed that SerpinB3 was more highly expressed
in PDX models than in human astrocytes (Figure S1E). Furthermore, SerpinB3 and JAM-A appear to stabilize each other, as
reduction of JAM-A in cultured GBM tumor cells resulted in the
reduction of SerpinB3 (Figure 1D). We also observed the reverse
effect (Figure S1F). We then measured SerpinB3 stability using a
cycloheximide chase assay. When JAM-A was knocked down,
SerpinB3 levels decreased more quickly than in control non-targeting (NT) conditions, further suggesting that JAM-A may function to stabilize SerpinB3 protein (Figure 1E). Together, these
data indicate that SerpinB3 is expressed under CSC-optimized
conditions in vitro and heterogeneously in CSCs and GBM
patient tumor specimens and that JAM-A is involved in the stabilization of SerpinB3.
Given the limited understanding of the role of SerpinB3 in
GBM, we sought to assess its function using a genetic depletion
approach. We used non-overlapping small hairpin RNAs
(shRNAs) against SerpinB3 and were able to reduce protein

(G) Fold change in cell viability at day 7, normalized to day 0, in 3 PDX glioblastoma models. Cell viability measured with CellTiter-Glo Luminescent Cell Viability
Assay (5 technical replicates per condition, per tumor model).
(H and I) Kaplan-Meier curves depicting survival of mice with 20,000 T4121 or T387 tumor cells intracranially injected. Cells were transfected with either non-target
(SHC002) or SerpinB3 (KD1 or KD2) shRNA, with n = 10 mice per group.
p < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by 1-way ANOVA with Dunnett’s multiple comparisons test or
log rank test for survival data. Error bars represent standard deviations.
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levels in multiple GBM PDX-derived CSC models (T4121, T387,
DI318) compared to NT controls (Figures 1F and S1G). While
initial experiments were performed using four different shRNAs
to demonstrate reproducibility, we subsequently focused on
two constructs, knockdown 1 (KD1) and knockdown 2 (KD2).
The reduction of SerpinB3 in CSCs resulted in a decreased number of viable cells in vitro (Figures 1G, S1H, and S1I) and a potent
reduction in tumor initiation and growth in vivo after intracranial
implantation into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (Figures 1H, 1I, and S1J). Taken together, these data provide evidence that SerpinB3 is essential for GBM CSC growth
and tumor initiation.
SerpinB3 promotes the CSC phenotype in GBM
Given the phenotypes observed upon SerpinB3 knockdown
in CSCs, we also assessed changes in CSC maintenance as a
result of SerpinB3 depletion. We observed that SerpinB3 knockdown reduced CSC signaling via changes in mRNA levels of core
pluripotency transcription factors (OCT4, NANOG, MYC), CSC
transcription factors (OLIG2), and known CSC maintenance factors (transforming growth factor-beta 1 [TGF-b1]) (Figures 2A and
S2A). We then interrogated the functional consequences of
SerpinB3 knockdown on self-renewal via in vitro limiting-dilution
assays, a surrogate for self-renewal that can also be affected by
cell proliferation and cell death, and found a potent reduction in
self-renewal with SerpinB3 knockdown compared to NT control
conditions across multiple CSC models (Figure 2B). To gain
further insight into SerpinB3-mediated changes, we focused
on c-MYC and TGF-b1 based on their reported roles in GBM
CSCs (Anido et al., 2010; Bruna et al., 2007; Wang et al.,
2008), essential role in cancer cell proliferation, and link to
SerpinB3 in HCC (Turato et al., 2014, 2015). As predicted, knockdown of SerpinB3 reduced c-MYC expression (Figure 2C) and
TGF-b1 secretion (Figure 2D). To gain additional mechanistic
insight into the role of SerpinB3 in CSC-mediated cell growth
and tumor initiation, we subjected SerpinB3-depleted CSCs to
a cancer-focused mRNA panel using the NanoString platform.
Using an unbiased clustering, we observed that NT control samples were distinct from SerpinB3 knockdown (using the KD2
construct) in two CSC models (T4121 and DI318; Figure S2B).
We found a series of pathways, including cancer driver genes
and a number of pathways known to regulate CSCs, including
Hedgehog, Notch, and TGF-b, that were differentially expressed
in NT control compared to SerpinB3-depleted cells (Figures 2E
and S2B). This finding corroborated our observation of reduced
TGF-b1 secretion with SerpinB3 knockdown (Figure 2D), and we
additionally validated that SerpinB3 depletion reduced the
expression of members of the Notch signaling network (NOTCH2
and JAGGED2; Figure S2C). We previously reported that JAM-A
signals through phospho-AKT; however, when we knocked
down SerpinB3, we saw no change in the phosphorylation
of AKT (Figure S2D), suggesting that SerpinB3 may signal
through a separate mechanism. SerpinB3 has been observed
within the nucleus (Katagiri et al., 2006), where it regulates
c-Jun N-terminal kinase (JNK1) kinase activity through a mechanism that has yet to be precisely elucidated. We also observed
SerpinB3 expression in SOX2+ nuclei, suggesting a potential
role in CSC maintenance within the nucleus (Figures 2F and
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S2E). These data indicate that SerpinB3 is essential for selfrenewal and interacts with multiple CSCs signaling network
nodes.
SerpinB3 protects GBM tumor cells from apoptotic
death
Based on the decrease in cell viability we observed after SerpinB3
knockdown and the well-established role for SerpinB3 in inhibiting
cell death, we asked whether this correlates with an increase in cell
death (Villano et al., 2014). Moreover, as our NanoString analysis
of cancer pathways also revealed an increase in apoptosis in cells
depleted of SerpinB3 (Figure 2E), we validated this increase
in apoptosis after SerpinB3 knockdown as read out by annexin
V/propidium iodide (PI) double-positive cells in multiple CSC
models (Figures 3A and S3A). SerpinB3 knockdown also resulted
in an increase in caspase 3/7 activity compared to control conditions using the CaspaseGlo DEVD-aminoluciferin assay. DEVD
is the canonical recognition site for Caspase-3 (Figures 3B and
S3B). In addition, we used the IncuCyte Caspase 3/7 assay, a
DEVD-tagged DNA-intercalating dye, which also demonstrated
increased caspase 3/7 activity (Figure 3C). Notably, the extent to
which SerpinB3 knockdown affected cellular functions appeared
to correlate with the degree of knockdown, with KD2 generally exhibiting a greater effect. Together, these data demonstrate an
enhanced cell death phenotype after the loss of SerpinB3.
SerpinB3 inhibits lysosomal-mediated apoptosis
As apoptosis can be initiated via multiple pathways (i.e., intrinsic
versus extrinsic), we sought to better understand the molecular
mechanism through which SerpinB3 prevents cell death.
SerpinB3 is a known inhibitor of cathepsin L (Sun et al., 2017),
a cysteine protease that relocalizes to the cytoplasm after
disruption of the lysosomal membrane or other acidic compartments, triggering ‘‘lysosomal-mediated cell death’’ (Figure 3D)
(Fehrenbacher et al., 2004; Oberle et al., 2010; Piazza et al.,
2007). To test whether SerpinB3 protects against lysosomalmediated cell death, we compromised lysosomal membrane
integrity using L-leucyl-L-leucine methyl ester (LLME) and
observed a potent decrease in cell viability, which was further
enhanced with SerpinB3 knockdown (Figures 3E, S3C, and
3D). To further determine whether the susceptibility of
SerpinB3 knockdown cells to LLME was due to a loss of the
cysteine cathepsin inhibitory function of SerpinB3, we used a
mutant of SerpinB3 with a deletion of six amino acids (D6) within
the hinge region of the reactive site loop (RSL). This SerpinB3
mutant protein is unable to inhibit cathepsin L activity (Sheshadri
et al., 2014). SerpinB3 KD2 cells were transfected with empty
vector (EV), wild-type SerpinB3, or SerpinB3 D6 and then treated
with either DMSO or LLME for 6 h. Following treatment, the percentage of annexin V+ cells was quantified. While wild-type
SerpinB3 was able to partially rescue cell death induced by
LLME treatment, the D6 mutant did not (Figure 3F). To determine
whether cathepsin L is driving in the cell death induced by LLME,
PDX tumor cells were treated with a high dose of LLME (3 mM)
for 6 h, and the percentage of annexin V+ and PI+ cells was calculated. Two distinct cathepsin L inhibitors, E64D and Z-FY-CHO,
reduced LLME-induced cell death (Figures S3E and S3F).
Finally, at a lower dose of LLME (1.5 mM), we observed a larger
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Figure 2. SerpinB3 regulates known CSC pathways
(A) RNA was isolated after SerpinB3 knockdown in T4121 cells, and qPCR was performed for SERPINB3, OCT4, NANOG, OLIG2, MYC, and TGF-b1 (3 technical
replicates).
(B) Tumor cells were plated in a limiting-dilution manner, and the number of wells containing spheres was counted after 14 days and used to calculate stem cell
frequencies using the online algorithm detailed in the methods. N = 12 wells per dilution.
(C) c-MYC expression after SerpinB3 knockdown was assessed via western blot, with actin as a loading control.
(D) TGF-b1 secretion was analyzed 2 days after plating and normalized to total protein (3 technical replicates per condition, per tumor model).
(E) NanoString pathway score comparing SerpinB3 knockdown to non-target control. Bolded rows represent pathways known to regulate the CSC state.
(F) Immunofluorescence staining of T4121 CSCs for SerpinB3 and SOX2. Scale bar represents 10 mM.
p < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by 1-way ANOVA with Dunnett’s multiple comparisons,
Student’s t test for qPCR data, or chi-squared p value for limiting dilution assay. Error bars represent standard deviations.
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Figure 3. SerpinB3 inhibits cell death
(A) The percentage of annexin V+ and propidium
iodide-positive (PI+) cells after SerpinB3 knockdown was compared to the non-target control
group (3 technical replicates per condition, per
tumor model).
(B) Activity of caspase 3/7 was measured using
Caspase-Glo after SerpinB3 knockdown, and the
fold change compared to the non-target control is
shown (3 technical replicates per condition, per
tumor model).
(C) Quantification of caspase 3/7 IncuCyte assay
normalized to cell confluence per well and
compared to the NT condition (4 technical replicates per condition, per tumor model).
(D) Schematic of lysosomal-mediated cell death
after treatment with L-leucyl-L-leucine methyl ester
(LLME).
(E) T4121 cells were treated with LLME at varying
concentrations for 7 days. On day 7, cell viability
was quantified via Cell Titer Glo and compared to
untreated DMSO controls for each condition. From
these values, the half-maximal inhibitory concentration (IC50) was determined (5 replicates per
condition).
(F) T4121 KD2 cells were transfected with DNA
encoding either SerpinB3, an empty vector (EV), or
a protease inhibitor-null mutant (D6). Cells were
then treated for 6 h with either 1.5 mM LLME or
DMSO control, and annexin V+ cells were quantified. The relative percentage increase compared to
DMSO-treated control was quantified, and the results of 3 independent experiments are graphed.
(G) T387 cells were treated with LLME or DMSO for
6 h with or without E64D. After 6 h, annexin V+/PI+
cells were quantified, n = 3 per condition.
p < 0.05 was considered statistically significant.
*p < 0.05, **p < 0.01, ***p < 0.001, as determined by
1-way ANOVA with Dunnett’s multiple comparisons or Student’s t test (F and G). Error bars
represent standard deviations.

increase in cell death induced by LLME in cells depleted of
SerpinB3, with only a minor increase in NT cells. This increase
was rescued by E64D treatment, demonstrating the role of
SerpinB3 in protecting cathepsin L-mediated cell death after
lysosomal membrane permeability (LMP) (Figure 3G). These
data demonstrate that SerpinB3 functions as a cathepsin L inhibitor in GBM CSCs and is responsible for inhibiting lysosomalmediated apoptosis.
Radiation induces lysosomal-mediated apoptosis
We next investigated whether standard-of-care radiation treatment could affect lysosomal membrane integrity (Figure 4A).
We observed an increase in LMP 6 h post-irradiation with a
single dose of 5 Gy as readout by a shift in acridine orange localization (Figures 4B, 4C, and S4A). Acridine orange fluoresces red
in acidic compartments and green in the remainder of the cell. In
addition, we observed a relocalization of cathepsin L from the
lysosome and other acidic compartments to the cytoplasm at
6 h after irradiation with a single 5-Gy dose (Figures 4D, 4E,
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and S4B). This can be observed as a shift in cathepsin L from
a primarily punctate structure to a more diffuse localization
throughout the cytoplasm. Importantly, we did not observe an increase in overall cathepsin L or SerpinB3 levels at this time point
or a meaningful increase in cell death (Figures S4C and S4D).
As radiation is part of the standard of care for GBM and as
CSCs are resistant to radiation, we next assessed whether the
depletion of SerpinB3 increases the efficacy of radiation in
CSCs. SerpinB3 knockdown potently increased the sensitivity
of CSCs to radiation compared to control NT conditions
(Figures 4F and S4E). We also observed increased cell death
24 h post-1.5 Gy radiation in SerpinB3 knockdown cells
compared to NT controls (Figures S4F and S4G). This increase
in cell death was rescued by both cathepsin L inhibitors E64D
and Z-FY-CHO in SerpinB3 KD1 cells (Figures 4G and S4H).
Notably, temozolomide (TMZ) did not result in increased cell
death, as TMZ does not induce LMP (Figure S4I) (Kanzawa
et al., 2004). Taken together, these data indicate that SerpinB3
protects against LMP induced by radiation.
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Figure 4. SerpinB3 buffers cells from lysosomal membrane permeability
(A) Schematic of lysosomal-mediated cell death
after radiation.
(B and C) Acridine orange was added to cells 6 h
after irradiation with 5 Gy, and images from 12
random visual fields were taken. The red:green
ratio per image was calculated comparing control
to irradiated conditions. Scale bar represents
25 mM.
(D and E) Six hours post-irradiation, cells were
fixed with paraformaldehyde and stained for
cathepsin L. The integrated density of cathepsin L
per cell was determined and compared between
the radiation and control conditions (12 images per
condition). Scale bar, 25 mM.
(F) Cell viability was measured after 2 days of
varying doses of radiation, and the percentage of
viable cells is shown compared to each group’s
untreated control at each dose of radiation (3
technical replicates per condition).
(G) T4121 tumor cells were treated with 2 Gy radiation with or without 30 mM E64D. Twenty-four
hours post-radiation, annexin V+/PI+ cells were
quantified, n = 3 per condition.
p < 0.05 was considered statistically significant.
*p < 0.05, **p < 0.01, ***p < 0.001, as determined by
1-way ANOVA with Dunnett’s multiple comparisons (F) or Student’s t test (C, E, and G). Error bars,
standard deviations.

SerpinB3 loss enhances the effects of radiation in vivo
To determine whether SerpinB3 is important for radiation resistance in vivo, we transplanted NT and SerpinB3-knockdown
T4121 CSCs and subjected the mice to a pre-clinical radiation
paradigm (Figure 5A). We found that SerpinB3 knockdown
increased tumor latency, and this was further extended by irradiation with 10 Gy over 5 days, increasing the hazard ratio in
SerpinB3 knockdown compared to control conditions
(Figures 5B–5E). This response was also observed with a lower
dose of radiation (Figures S5A–S5E). Taken together, these
data suggest that SerpinB3 prevents cell death and contributes
to radiation resistance.
DISCUSSION
Resistance to apoptosis is a well-recognized hallmark of cancer,
but specific resistance mechanisms underlying cell death have
not been thoroughly investigated in CSCs. This is surprising given

that the predominant phenotype of CSCs
is enhanced therapeutic resistance, specifically to radiation and temozolomide in
the case of GBM. SerpinB3 represents a
mechanism for GBM CSC survival that
may also be functionally important in other
cancers. The role of SerpinB3 in cancer is
not well developed, despite being originally identified as overexpressed in SCC
(Kato and Torigoe, 1977). Studies in cervical cancer, non-small cell lung cancer,
breast cancer, esophageal SCC, and HCC have correlated
elevated SerpinB3 expression with clinical stage and decreased
response to therapy (Collie-Duguid et al., 2012; Liu et al., 2015;
Ngan et al., 1990; Petty et al., 2006; Shimada et al., 2003; Wang
et al., 2022). The role of SerpinB3 in GBM had not been studied until recently, when a long non-coding RNA (lncRNA), TMEM44-AS1
(Bian et al., 2021), was found to bind to SerpinB3, forming a positive feedback loop with MYC. While this suggests the importance
of SerpinB3 in GBM, the detailed molecular mechanism(s) by
which SerpinB3 drives oncogenesis in its role in therapy resistance
have yet to be fully elucidated.
There are several hypothesized mechanisms by which
SerpinB3 could affect cancer-relevant phenotypes (e.g., impact
on the stem cell state, resistance to apoptosis, invasion). A
recent study in cholangiocarcinoma found that SerpinB3 was expressed in a stem-like subset of cells and that knockdown of
SerpinB3 resulted in decreased invasion and proliferation (Correnti et al., 2021). In addition to its roles in cancer, SerpinB3 is
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Figure 5. SerpinB3 contributes to radiation resistance
(A) Schematic of in vivo radiation experiment with 10 Gy total radiation treatment.
(B–E) A total of 20,000 tumor cells per condition were intracranially injected into 10 mice per group. Ten days after irradiation, mice received 2 Gy of radiation per
day for 5 days (total of 10 Gy) to the head. (B) All of the treatment groups are shown together with median survival values given. The groups were subsequently
divided into (C) non-target with or without radiation, (D) SerpinB3 KD 1 with or without radiation, and (E) SerpinB3 KD 2 with or without radiation.
*p < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by log rank test.

expressed in hepatic stem cells, where SerpinB3 expression
correlates with decreased activated caspase 3 (Villano et al.,
2014). SerpinB3 has been linked to the inhibition of apoptosis
in the settings of endoplasmic reticulum stress (Verfaillie et al.,
2013), tumor necrosis factor-a (TNF-a) release (Suminami
et al., 2001), radiation (Murakami et al., 2001), and ultraviolet
radiation (Katagiri et al., 2006), but the exact mechanism is
unknown. In this study, we have highlighted the role of lysosomal
membrane permeability and cathepsin L release as a mechanism of resistance to apoptosis. SerpinB3 inhibits cathepsin L
(Sun et al., 2017), and cathepsin L released from the lysosomes
and other acidic compartments has been shown to cause caspase-mediated cell death (Fehrenbacher et al., 2004; Oberle
et al., 2010). Finally, while multiple mechanisms of radiationinduced cell death have been documented, our study builds on
earlier work highlighting the role of lysosomal membrane permeability in sensitizing tumor cells to radiation in GBM (Zhou et al.,
2020). A recent paper found a similar role for SerpinB3 in inhibiting cathepsin L in cervical cancer post-radiation (Wang et al.,
2022). Taken together, these data outline a mechanism whereby
SerpinB3 expressed in GBM tumor cells leads to radiation resistance by buffering lysosomal membrane permeability.
Targeting the CSC state remains a clinically interesting possibility, and our observations suggest that SerpinB3 inhibition may
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be a mechanism by which cells with a CSC phenotype can be
sensitized to radiation. Our observations, the upregulated
expression of SerpinB3 in other cancers, and the dependence
of other tumor cells on SerpinB3 (Figures S5F and S5G) set
the foundation for additional studies of stem-like cells in other tumor types. In this manuscript, we have demonstrated a role for
SerpinB3 in both the maintenance of the CSC state and in resistance to apoptosis. We have shown that JAM-A binds to
SerpinB3 and is involved in its stabilization. In addition, the
loss of SerpinB3 has led to decreased expression of multiple
well-established CSC transcription factors and pathways.
Limitations of the study
There are several limitations to this study. From a technical
perspective, our tumor models were grown in CSC-enriching
sphere conditions, which does not recapitulate the complex tumor microenvironment in terms of tumor cell state or consider
other cell types such as neurons and astrocytes. Moreover, our
radiation methods fail to recapitulate the hypoxic microenvironment of the tumor within the human brain. From a conceptual
perspective, we used three different GBM tumor models, which
does not recapitulate the entire spectrum of heterogeneity
observed in GBM, and the function of SerpinB3 may vary across
different tumors.
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Conclusions and future directions
Future priorities include the development of brain-penetrant
SerpinB3 inhibitors. The flexibility of the protease inhibitor
domain represents one developmental challenge, along with
the high degree of homology between SerpinB3 and SerpinB4
outside the protease inhibitor region. These challenges necessitate a further understanding of this signaling network, including
JAM-A-dependent versus -independent functions of SerpinB3
and the importance of JAM-A SerpinB3 stability, localization,
and function. Another consideration for therapeutic development is the impact on cell death, which is a fundamental process
in organ development and homeostasis in healthy tissue.
The extent to which the inhibition of SerpinB3 may serve
as a transforming event for cancer initiation should be an additional consideration. Finally, the exact mechanism by which
SerpinB3 maintains the CSC phenotype remains incompletely
understood. This mechanism may involve the regulation of
c-MYC, with the changes in CSC state downstream of MYC, or
SerpinB3 may interact with other transcription factors within
the nucleus that regulate the CSC state. Whether this maintenance is dependent on protease inhibition has also yet to be
explored.
SerpinB3 has emerged as a molecule of interest across
numerous tumor types and further research into mechanisms
for targeting SerpinB3 is required moving forward. In summary,
our findings suggest that SerpinB3 may be a targetable mechanism leveraged by CSCs to resist cell death.
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pLPC-N FLAG vector

Addgene

#12521; RRID:Addgene_12521

Fugene HD

Promega

E2311

Software and algorithms
LASX software

Leica
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IncuCyte SX5 Live-Cell Analysis Instrument

Sartorius
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live-cell-imaging-analysis/live-cell-analysisinstruments/sx5-live-cell-analysis-instrument

nSolver version 4.0

Nanostring

N/A

ELDA

Hu and Smyth, 2009

http://bioinf.wehi.edu.au/software/elda/index.
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Applied Biosystems QuantStudio 3

Thermo Fisher
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https://imagej.net/downloads
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Justin D.
Lathia (lathiaj@ccf.org).
Materials availability
This study did not generate new unique reagents.
Data and code availability
d Accession numbers are listed in the key resources table. DOI link to original western blot images is available in key resources
table. Microscopy data reported in this paper will be shared by the lead contact upon request.
d This paper does not report original code.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
GBM tumor cell derivation and culture
GBM tumor models were generated by passaging primary tumor cells through immunocompromised mice as previously
described (Bao et al., 2006; Lathia et al., 2010). Briefly, primary tumor cells were intracranially implanted into NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice (male or female), and upon tumor formation, tumors were isolated and digested with papain (Worthington). Dissociated cells were plated overnight in Neurobasal Medium minus phenol red (ThermoFisher) with 13 B27 supplement (ThermoFisher, #17504001), 1 mM sodium pyruvate, 2 mM L-glutamine, 50 U/mL penicillin/streptomycin, 20 ng/mL human
(h)EGF and 20 ng/mL hFGF2 (R&D systems). Subsequently, CD133+ cells were isolated by magnetic bead sorting (Miltenyi,
#130-097-049) and cultured in the media described above. Some cell models were previously established at Duke University
and obtained through approved material transfer agreements. CD133+ cells were seeded in suspension culture at 5 3 104
cells/mL and passaged no more than 10 times. After 10 passages, cells were re-implanted subcutaneously into the flank of
NSG mice and enriched for CD133+ cells. Cells were routinely checked for mycoplasma using MycoAlert detection kit (Lonza,
LT07-118) and all cells were prophylactically treated with low dose mycoplasma removal agent (MP bio 093050044) after initial
CSC isolation. De-identified GBM specimens were collected from the Cleveland Clinic Brain Tumor and Neuro-Oncology Center
in accordance with an Institutional Review Board-approved protocol, and informed consent was obtained from all GBM patients
contributing tumor specimens. The gender information of the tumors is not known. Human astrocytes from cerebral cortex were
obtained from ScienCell Research Laboratories (#1800).
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Intracranial implantation
Intracranial tumor transplants were performed as described previously (Bayik et al., 2020). Six to 8 week old NSG mice were anesthetized with inhaled isoflurane for the duration of the procedure. Initial survival studies were done with both male and female mice.
After no sex difference was observed, the remainder of the experiments were performed on male mice. A total of 20,000 T4121 or
T387 CSCs infected with control or SerpinB3 shRNAs were suspended in 10 mL Neurobasal null medium and stereotactically
implanted into the left hemisphere 2.5 mm deep into the brain. In relevant experiments, on day 10 after implantation, mice were
anesthetized with xylazine (0.13 mg/mouse) and ketamine (1.3 mg/mouse) and exposed to 2 Gy radiation for either 3 or 5 days
(PANTAK) starting 10 days post-tumor implantation and shielding the body with lead. Mice were monitored for neurologic signs
and weight loss and deemed at endpoint when exhibiting any of these symptoms. Endpoint mice were transcardially perfused using
4% paraformaldehyde, and the brains were dissected for histological analysis after at least 48 h in 4% paraformaldehyde. All experiments were performed in compliance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic (protocol 2019–2195 and 2019–2299).
In a separate experiment, 5 mice per group were sacrificed at a predetermined endpoint of 21 days after injection of T4121 cells (2
NT mice died before the endpoint and were not included). At 21 days, mice were perfused, and brains were collected. Sections were
cut at three different levels for each brain and subjected to hematoxylin and eosin staining. The largest tumor cross-section for each
brain was identified and ImageJ was utilized to quantify the area of the entire brain and area of the tumor. The tumor proportion of the
cross-section was calculated and graphed.
METHOD DETAILS
Immunoblotting
Protein was isolated from cells using a lysis buffer composed of 10 mM Tris HCl, 1 mM EDTA, 150 mM NaCl, 0.5% NP-40, 1 mM
PMSF, 13 protease inhibitor (Sigma, #p8340), and 13 phosphatase inhibitor cocktail (Sigma, #p5726). Cells were intermittently incubated with the lysis buffer on ice and vortexed three times before being spun down for 10 min at 14,000 rpm. Protein concentrations
were measured using bovine serum albumin for the protein standard and protein assay dye (Bio-Rad). A total of 40 mg of protein per
condition was denatured with SDS-PAGE sample buffer and then loaded into polyacrylamide SDS-PAGE gels. The gels were run at
120 volts for 80 min and then transferred onto PVDF membranes (Millipore). The membranes were then blocked with 5% nonfat milk
and probed with the appropriate primary antibody: SerpinB3 (Invitrogen PA5-30164, 1:5000), JAM-A (B&D Biosciences 612120,
1:1000), cathepsin L (ThermoFisher BMS1032, 1:5000), AKT (Cell Signaling, 9272), phosphoAKT (Ser473)(Cell Signaling, 4075A)
and c-MYC (Cell Signaling Technology 5605, 1:5000). b-Actin (Bio-Rad 12004163, 1:10,000) was used as a loading control. Secondary antibodies specific to the species of the primary antibody conjugated to horseradish peroxidase were added to the membranes:
anti-rabbit (Invitrogen) and anti-mouse (EMD Millipore). Membranes were developed with Pierce ECL 2 Western Blotting Substrate
(Thermo Scientific) onto film. For some experiments, secondary antibody was conjugated to StarBright 700 (Bio-Rad 12004161). For
these experiments, a Bio-Rad Chemidoc MP was used to image the blots.
Affinity purification of His-tagged JAM-A
T4121 CSCs were transiently transfected with N-terminal His-tagged full-length JAM-A (Sinobiologicals, HG10198-NH). The Histagged JAM-A was pulled down and isolated with nickel beads. Mass spectrometric analysis was used to identify binding partners
that were pulled down along with JAM-A. For protein digestion, the bands were cut from the gel, washed/destained in 50%
ethanol/5% acetic acid and then dehydrated in acetonitrile. The bands were then reduced with DTT and alkylated with iodoacetamide
prior to in-gel digestion. Bands were digested overnight in-gel using trypsin. The peptides that were formed were extracted from the
polyacrylamide in 50% acetonitrile with 5% formic acid. These extracts were combined and evaporated to <10 mL in a Speedvac and
then resuspended in 1% acetic acid. The LC-MS system was a Finnigan LTQ-Obitrap Elite hybrid mass spectrometer system. The
HPLC column was a Dionex 15 cm 3 75 mm id Acclaim Pepmap C18, 2 mm, 100 Å reverse phase capillary chromatography column.
The digest was analyzed using the data-dependent multitask capability of the instrument acquiring full-scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. The
data were analyzed by using all CID spectra collected in the experiment to search the human UniProtKB database with the search
program Mascot. These partners were cross-referenced with the contaminant repository for affinity purification to remove negative
controls.
Immunostaining
Cells were plated onto coverslips in 6 well plates, fixed with 4% paraformaldehyde, blocked in donkey serum with 0.1% Triton X-100,
and then incubated with the appropriate primary antibody (SerpinB3; PA5-30164 Invitrogen, 1:500, JAM-A; Santa Cruz sc-53623,
1:500, SOX2; R&D, MAB2018) followed by a species-specific secondary antibody. Secondary antibodies were as follows,
donkey-anti mouse Alexa Fluor 555 (ThermoFisher) and donkey-anti rabbit Alexa Fluor 488 (ThermoFisher). The cells were then
stained with Hoechst 33,342 (Invitrogen H3570, 1:3000) before being mounted with Vectashield (Vector Labs) onto glass cover slides
and imaged using a confocal microscope.
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Lysosomal membrane permeability post irradiation
T4121 tumor cells were treated with 5 Gy radiation. After 6 h, 2 mg/mL acridine orange (Sigma A6014) was added for 30 min, and
media was replaced before live cells were imaged.
For cathepsin L staining, tumor cells were treated with 5 Gy radiation and fixed with 4% formaldehyde after 6 h. Cathepsin L antibody (ThermoFisher BMS1032, 1:1000) was added overnight, secondary antibody was then added (donkey-anti mouse Alexa Fluor
488, ThermoFisher), and Hoechst 33342 (Invitrogen H3570, 1:3000) was utilized as a nuclear counterstain.
Confocal microscopy
All images were taken with an inverted Leica SP8 confocal microscope at 403 magnification at room temperature. The LASX software was utilized for image acquisition. For image analysis, Fiji software was utilized. For quantification, images were split into individual channels, and the ‘‘integrated density’’ tool was utilized to quantify intensity of each channel per image. When quantifying the
total number of cells, nuclei were counted manually.
Immunohistochemistry on human glioblastoma
Standard immunohistochemistry analysis was performed on two patient specimens with a diagnosis of primary IDH-wild-type GBM
using SerpinB3 antibody (Invitrogen, PA5-30164) diluted at 1:1000. Four-micrometer thick sections of FFPE tissue on charged slides
were baked in the oven at 60C for 60 min before being deparrafinized and re-hydrated. Antigen retrieval was achieved using a pH6
retrieval buffer (Biocare Reveal). Slides were cooled to room temperature and washed in TBS before neutralizing endogenous peroxidase (Biocare Peroxidase 1). Slides were then treated with a serum-free casein background block (Biocare Background Sniper)
before pre-incubation in a 10% goat serum block for 60 min. Primary antibody was then added to the slides for overnight incubation
at 4C. After incubation, slides were washed well with TBS-T before incubating in HRP polymer (Biocare MACH 4 Universal HRP Polymer). Finally, reaction products were visualized with DAB (Biocare Betazoid DAB Chromogen Kit). Slides were then counterstained
with hematoxylin, dehydrated and mounted with xylene-based mounting media.
Cycloheximide protein stability assay
T387 and T4121 CSCs were stably transduced with JAM-A KD-2 or SHC002 shRNA constructs. Cells were plated into a 12 well dish
with 100,000 cells per well. Cycloheximide (Alfa Aesar, #J66004) was added to all wells except the control. Cells were collected 6 and
12 h after addition of cycloheximide and protein was isolated and run on Western blot that was blotted for SerpinB3 (Invitrogen
PA5-30164, 1:5000) with actin as loading control.
SerpinB3 overexpression mutants
SerpinB3 overexpression vectors were obtained from the Zong lab and were developed as previously described (Sheshadri et al.,
2014). These included a wild-type SerpinB3 in the pLPC-N Flag vector (Addgene, #12521) as well as an empty vector and a mutant
SerpinB3 with amino acids 340–345 deleted (D6). Cells were transfected with Fugene HD (Promega, E2311) at an optimized ratio with
Opti-mem. After 12 h, media was replaced, and cells recovered for 2 days before treatment with LLME (1.5 mM) and assessment of
apoptosis as described below.
Stable transduction with lentiviral shRNA and overexpression construct
MISSION pLKO.1-puro Non-Mammalian shRNA Control Plasmid (SHC002) and SerpinB3 shRNA plasmids TRCN0000373440
(KD1), TRCN0000373501 (KD2), TRCN0000052398 (KD3) and TRCN0000373500 (KD4) were purchased from Sigma. These correspond to four non-overlapping single shRNAs. Lentivirus was packaged in 293 T cells using psPAX2 and pMD2G using calcium
phosphate transfection, and media containing lentiviral particles were collected. This supernatant containing lentiviral particles
was concentrated using PEGit virus precipitation solution according to the manufacturer’s protocol (System Biosciences). JAM-A
knockdown constructs were as follows: TRCN0000061650 (KD1) and TRCN0000061649 (KD2).
Prior to transfection, CSCs were grown adherently on 6 well plates pretreated with Geltrex (Life Technologies, A1413301). Lentivirus was added to and incubated with the cells for 24 h. Then cells were grown in their appropriate media for 24 h, after which
selection with puromycin (ThermoFisher, 54-022-2100) was initiated. Transfected cells were incubated in media with puromycin
(1 mg/mL stock) at 1:333 for 48 h. Stably transfected cells were maintained in their regular media plus puromycin at 1:1000.
Cellular viability
Cellular viability was measured by plating each line of interest in triplicate in a 96-well plate at a density of 1000 cells/100 mL media per
well. ATP levels at day 0 and day 7 were measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega). For analysis, day 7
was normalized to the day 0 measurement.
To measure cell count over time, cells were plated in triplicate in a Geltrex-coated 96-well plate at a density of 1000 cells/100 mL
media per well. The 96-well plate was then placed in the IncuCyte SX5 Live-Cell Analysis Instrument, and images were taken every 8 h
for 7 days. The cell-by-cell software was then utilized to determine cell count per well, and these values were normalized to the time
0 cell count.
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NanoString
RNA was isolated using an RNeasy mini kit (Qiagen), and then the nCounter PanCancer Pathways Panel was used to analyze RNA
expression. Two tumor models (T4121 and DI318) were analyzed in triplicate in each condition (non-target and SerpinB3 knockdown
(KD2)). nSolver version 4.0 was utilized to determine pathway alterations.
TGF-b ELISA
R&D systems human TGF-b1 DuoSet ELISA catalog# DY240 was used to quantify TGF-b1 in vitro from conditioned media isolated at
day 2 after plating 200,000 cells per well in a 12 well plate with 1.5 mL of complete Neurobasal media. Output was normalized to total
protein concentration in the pellet to control for changes in cell viability.
Radiation treatment
A total of 50,000 cells per well were plated in triplicate in a 12 well plate. Cells were then irradiated with varying doses of radiation.
On day 2, cell viability was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega). Viability was normalized to the
untreated control for each condition and graphed as a percentage of the total.
For post-radiation apoptosis assays, cell were irradiated and when indicated, cathepsin L inhibitors E64D (Enzo, #PI107-0001) and
Z-FY-CHO (Med Chem Express, #HY-128140) were added immediately after radiation. Cells were incubated for 24 h, then treated
with Accutase (Biolegend, #42320) to ensure a single-cell suspension and stained with annexin V and propidium iodide as described
below. Double positive cells were quantified. A similar experiment was performed with Temozolomide (Santa Cruz, #CAS 8562293-1) as a replacement for irradiation.
L-leucyl-L-leucine methyl ester IC50
A total of 4,000 cells per well was plated in 96 well plate in quintuplets. L-leucyl-L-leucine methyl ester (LLME, Cayman #16008) was
added over a range of concentrations. After 7 days of treatment, cell viability was measured, and half-maximal inhibitory concentrations (IC50) for each condition were calculated.
L-leucyl-L-leucine methyl ester apoptosis assay
Cells were plated in triplicate in a 12 well dish with 50,000 cells per well. LLME or a DMSO control was added into appropriate wells.
Cathepsin L inhibitors E64D (Enzo, #PI107-0001) and Z-FY-CHO (Med Chem Express, #HY-128140) were added at the same time.
After 6 h, cells were stained with annexin V and propidium iodide as described below and double-positive cells were quantified.
Limiting-dilution analysis
Cells were plated at 100 cells per well in 12 wells of a 96 well plate, and two-fold serial dilutions were performed. Twelve wells of each
cell dose were plated. Limiting dilution plots and stem-cell frequencies were calculated using ELDA analysis (http://bioinf.wehi.edu.
au/software/elda/index.html (Hu and Smyth, 2009)).
Cell death
For caspase activity assays, cells were plated in quintuplicate at 10,000 cells/well in 96 well plates for 48 h. Caspase 3/7 activity was
determined with the Caspase-Glo 3/7 assay (Promega, G8090) and caspase activity was normalized to cell number by performing the
CellTiter-Glo Luminescent Cell Viability Assay on the duplicate plate.
Additionally, cells were plated for imaging in an IncuCyte as described above, and 5 mM Caspase 3/7 dye was included in the media
(Sartorius, #4704). The number of red nuclei (indicating active caspase 3/7) was divided by the area confluence per well. These values
were then normalized to the non-target control.
For annexin V and propidium iodide assay, 25,000 cells/well were plated in 1.5 mL of Neurobasal media. After 48 h, a single-cell
suspension was obtained, and FITC-labeled annexin V and propidium iodide were added in accordance with the protocol
(BioLegend, #640914). Samples were run on an LSR Fortessa flow cytometer (BD Biosciences) with a minimum of 10,000 events
collected. Single cells were gated, and the percentage of annexin V- and PI-positive cells was determined.
JAM-A and SerpinB3 coexpression
The percentage of PDX GBM CSCs that co-expressed SerpinB3 and JAM-A was determined with flow cytometry. GBM CSCs
were grown as spheres treated with Accutase to form a single-cell suspension. Cells were treated with LIVE/DEADTM Fixable
Blue Dead Cell Stain Kit (Invitrogen, L23105) at a 1:1,000 dilution in Mojosort buffer (Biolegend, #480017). After washing, JAM-A
AF647 (Invitrogen, #00-5523) was added and incubated for 10 min. Cells were then fixed overnight. The next day, cells were washed
in permeabilization buffer. Post-wash, either SerpinB3 or CD4 intracellular control was added to the cells. Cells were again washed,
and donkey-anti rabbit Alexa Fluor 488 was added. Cells were then run through an LSR Fortessa flow cytometer (BD Biosciences)
with a minimum of 10,000 events collected.
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Real-time reverse transcription polymerase chain reaction
RNA was collected from cells using an RNeasy kit (Qiagen, 74004). RNA concentrations were measured using a NanoDrop spectrophotometer, and cDNA was synthesized with qScript synthesis reagent (Quanta Biosciences, 95048). qPCR was run with the primers
shown in Table S2 using SYBR-Green Mastermix (SA Biosciences, 4385610) and an Applied Biosystems QuantStudio 3. During analysis, threshold cycle numbers were normalized to GAPDH or Actin levels.
Depmap RNAi
The RNAi DEMETER2 analysis framework was utilized to determine the gene dependency of SerpinB3 (McFarland et al., 2018). Data
was accessed from https://depmap.org/R2-D2/ on 12/12/2021 and relied on three large RNAi datasets (Marcotte et al., 2016; McDonald et al., 2017; Tsherniak et al., 2017).
Bioinformatics
On May 12th, 2022, the TCGA glioblastoma Agilent-4502A dataset was accessed via http://gliovis.bioinfo.cnio.es/. SerpinB3 expression was compared across GBM subtypes.
QUANTIFICATION AND STATISTICAL ANALYSIS
For two-group comparisons, p values were calculated using Student’s t Test. For multiple group comparisons, one-way ANOVA with
Dunnett’s multiple comparisons test was used as indicated in the figure legends. Log rank tests were used for survival analysis.
GraphPad Prism 6 was used for statistical tests. All in vitro experiments were done in at least technical triplicates for each experimental group, and multiple independent experiments were performed. The Grubb’s test was performed to determine whether any
outliers were statistically different. All figures graph mean and standard deviation. Statistical details can be found in figure legends.
p < 0.05 was considered statistically significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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